Searchable abstracts of presentations at key conferences in endocrinology

ea0077p42 | Metabolism, Obesity and Diabetes | SFEBES2021

Chronic inflammation regulates androgen metabolism and exposure in Macrophages

Martin Claire S , Kalirai Matthew Singh , Crastin Ana , Turner Jason D , Schiffer Lina , Gilligan Lorna C , Taylor Angela E , Scheel-Toellner Dagmar , Raza Karim , Filer Andrew , Jones Simon W , Arlt Wiebke , Hewison Martin , Hardy Rowan S

Active androgens exert immunomodulatory actions at sites of inflammation and lower levels are implicated in the increased incidence of rheumatoid arthritis (RA) in females. However, inflammatory regulation of intracrine androgen metabolism within cell populations at sites of inflammation remain poorly defined. In this study we characterised immune and stromal cell androgen metabolism in RA patients and assessed their functional significance. Using the online Accelerating Medic...

ea0078oc4.7 | Oral Communications 4 | BSPED2021

The use of urinary steroid profiles in monitoring therapy in children with 21-hydroxylase deficiency – results from the CAH-UK cohort study

Bacila Irina , Lawrence Neil , Alvi Sabah , Cheetham Timothy , Crowne Elizabeth , Das Urmi , Dattani Mehul , Davies Justin H , Gevers Evelien , Krone Ruth , Kyriakou Andreas , Patel Leena , Randell Tabitha , Ryan Fiona , S Faisal Ahmed , Keevil Brian , Taylor Norman , Krone Nils

Introduction: Monitoring glucocorticoid (GC) replacement in patients with congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency (21OHD) remains challenging. There are disease-specific patterns in the plasma and urinary steroid profiles in 21OHD, a key role being played by the 11-oxygenatedC19 androgens. Aim: To explore the urinary steroid profile in 21OHD in relation to treatment and plasma steroids. Methods: Partic...

ea0050oc1.3 | Early Career Oral Communications | SFEBES2017

Antioxidant pathway targeting as a therapeutic approach in adrenocortical carcinoma

Chortis Vasileios , Taylor Angela E. , Doig Craig L. , Meimaridou Eirini , Walsh Mark , Jenkinson Carl , Rodriguez-Blanco Giovanny , Jafri Alisha , Ronchi Cristina , Metherell Louise A. , Hebenstreit Daniel , Dunn Warwick B. , Arlt Wiebke , Foster Paul A.

Adrenocortical Carcinoma (ACC) is an aggressive malignancy with poor response to chemotherapy. Here we evaluated a potential new treatment target for ACC, focusing on the mitochondrial NADPH generator Nicotinamide Nucleotide Transhydrogenase (NNT). NNT has a central role within the mitochondrial antioxidant pathways, protecting cells from oxidative stress. Inactivating NNT mutations lead to isolated primary adrenal insufficiency, suggesting a selective vulnerability of adrenoc...

ea0050oc1.3 | Early Career Oral Communications | SFEBES2017

Antioxidant pathway targeting as a therapeutic approach in adrenocortical carcinoma

Chortis Vasileios , Taylor Angela E. , Doig Craig L. , Meimaridou Eirini , Walsh Mark , Jenkinson Carl , Rodriguez-Blanco Giovanny , Jafri Alisha , Ronchi Cristina , Metherell Louise A. , Hebenstreit Daniel , Dunn Warwick B. , Arlt Wiebke , Foster Paul A.

Adrenocortical Carcinoma (ACC) is an aggressive malignancy with poor response to chemotherapy. Here we evaluated a potential new treatment target for ACC, focusing on the mitochondrial NADPH generator Nicotinamide Nucleotide Transhydrogenase (NNT). NNT has a central role within the mitochondrial antioxidant pathways, protecting cells from oxidative stress. Inactivating NNT mutations lead to isolated primary adrenal insufficiency, suggesting a selective vulnerability of adrenoc...

ea0083ao2 | Adrenal and Cardiovascular | EYES2022

Combining steroid and global metabolome profiling by mass spectrometry with machine learning to investigate metabolic risk in benign adrenal tumours with mild autonomous cortisol secretion

A Prete , L Abdi , M Canducci , A. E. Taylor , L. C. Gilligan , A Albors-Zumel , E van den Brandhof , Y Zhang , K. N. Manolopoulos , P Tino , M Biehl , W. B. Dunn , W Arlt

Background: Benign adrenal tumours are discovered in 3-10% of adults and can be non-functioning (NFAT) or associated with adrenal hormone excess, most frequently mild autonomous cortisol secretion (MACS) defined by the failure to suppress cortisol after 1 mg dexamethasone overnight but lack of distinct signs of Cushing’s syndrome (CS). We found that MACS increases the prevalence and severity of type 2 diabetes and hypertension and primarily affects women (Ann Int Med. 202...

ea0065ec1.2 | Early Career Prize Lecture Translational | SFEBES2019

From bench to bedside and beyond: a novel therapy to improve wound healing in type 2 diabetes

Ajjan Ramzi , Hensor Elizabeth , Abbas Afroze , Galdo Francesco Del , Russell David , Shams Kave , Stewart Paul , Webber Lorraine , Pegg Lindsey , Freeman Adrian , Woods Janet , Eng Sookhoe , Taylor Angela , Arlt Wiebke , Tahrani Abd , Tiganescu Ana

The International Diabetes Federation estimates that type 2 diabetes mellitus (T2DM) will affect 642 million people by 2040. Chronically inflamed, hypoxic wounds are common in T2DM and represent a global unmet clinical need. Each year, diabetic foot ulcers cost the NHS £650 million and cause 1 in 200 UK deaths. This mortality is greater than colon, breast and prostate cancer combined. Glucocorticoids are used to treat a range of inflammatory conditions (e.g. asthma, eczem...

ea0065oc1.1 | Metabolism and Obesity | SFEBES2019

Intracrine activation of 11-oxygenated androgens by AKR1C3 modulates lipid metabolism in human female adipose tissue

Schiffer Lina , Sinclair Alexandra J , O'Reilly Michael W , Westgate Connar , Mashood Afeefa , Palmer Elliot , Gilligan Lorna C , Singhal Rishi , Taylor Angela E , Dunn Warwick B , Arlt Wiebke , Storbeck Karl-Heinz

Polycystic ovary syndrome (PCOS) affects 10% of women and is associated with an increased risk of type 2 diabetes and fatty liver disease. Androgen excess is an important driver of metabolic risk in PCOS. In adipose tissue from women with PCOS, increased activation of androstenedione (A4) to testosterone (T) by the enzyme AKR1C3 results in systemic lipotoxicity. Recent in-vitro studies also demonstrated that T and 11-ketotestosterone (11KT) activate the androgen recep...

ea0063gp179 | Benign Thyroid Disorders | ECE2019

Long-term cardiometabolic effects of maternal sub-optimal gestational thyroid function and relative treatment in the Controlled Antenatal Thyroid Screening (CATS) study II

Muller Ilaria , Taylor Peter , Daniel Rhian , Hales Charlotte , Scholz Anna , Yin Xiaochen , Candler Toby , Pettit Rebecca , Evans William , Shillabeer Dionne , Draman Mohd , Dayan Colin , Tang Carolyn , Okosieme Onyebuchi , Gregory John , Lazarus John , Rees Aled , Ludgate Marian

Introduction: The effects of maternal suboptimal gestational thyroid function (SGTF) on age 3 offspring’s cognitive function were investigated in the Controlled Antenatal Thyroid Screening (CATS) randomised trial, comparing SGTF mothers who received (SGTF-T), or didn’t (SGTF-U), levothyroxine during pregnancy. The analysis was repeated at age 9 in the CATS-II follow-up study, also including children of mothers with normal gestational thyroid function (NGTF). Here we ...

ea0044oc6.3 | Pregnancy and Reproductive Health | SFEBES2016

Controlled Antenatal Thyroid Screening Study; Obstetric Outcomes

Taylor Peter , Lacey Arron , Thayer Daniel , Draman Mohd , Tabasum Arshiya , Muller Ilaria , Marsh Luke , Poacher Arwel , Roberts Aled , Ludgate Marian , Rees Alex , Boelaert Kristien , Rees Aled , Chan Shiao , Lazarus John , Nelson Scott , Vaidya Bijay , Okosieme Onyebuchi

Context: Suboptimal thyroid function in pregnancy is associated with adverse obstetric outcomes but it is unclear whether levothyroxine treatment, initiated during pregnancy is beneficial.Design & Participants: Retrospective analysis of the Controlled Antenatal Thyroid Screening (CATS) study with obstetric outcomes obtained through data-linkage in the Secure Anonymised Information Linkage (SAIL) databank. We studied 13,224 pregnant women; 12,608 had ...

ea0059p200 | Thyroid | SFEBES2018

Controlled Antenatal Thyroid Screening (CATS) II: long-term cardiometabolic effects of treating maternal sub-optimal thyroid function

Muller Ilaria , Daniel Rhian , Hales Charlotte , Scholz Anna , Yin Xiaochen , Candler Toby , Pettit Rebecca , Evans William , Taylor Peter , Shillabeer Dionne , Draman Mohd , Dayan Colin , Tang Carolyn , Okosieme Onyebuchi , Gregory John , Lazarus John , Rees Aled , Ludgate Marian

Objectives: The Controlled Antenatal Thyroid Screening (CATS) study I was a randomised trial investigating the effects of levothyroxine treatment for suboptimal gestational thyroid function (SGTF), evaluating mothers with normal gestational thyroid function (NGTF), SGTF who received (SGTF-T), or didn’t (SGTF-U), levothyroxine during pregnancy. The present follow-up study (CATS II) reports the long-term effects of SGTF and levothyroxine treatment on anthropometric and card...